Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bladder Cancer: Positive Signs For Tecentriq, Seattle Genetics Shines

Executive Summary

Middling data for Roche’s IO plus chemo combo were presented at ESMO, while Seattle's rival drug antibody conjugate posted an impressive Phase I response rate.

You may also be interested in...



Padcev Sales Exceed Expectations As Seattle Genetics Pursues Earlier Indications

The bladder cancer drug delivered $34.5m in its first full quarter of sales – four times analyst consensus for Q1 – and Padcev’s market may grow rapidly based on results from ongoing studies.

Eight Talking Points From ESMO

Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.

Ten Strategies For Success In Antibody-Drug Conjugate Development

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel